NASDAQ$EOLS
Evolus Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Evolus reported Q4 2020 results, with net revenue reaching an all-time high and strategic balance sheet transactions completed.
Evolus reported Q4 2020 net revenue of $20.6 million, the highest since the launch of Jeuveau. The company also successfully transformed its business by settling the ITC case and related litigation, eliminating $127 million of debt and payment obligations, and strengthening its cash position.
- Net revenue for Q4 2020 reached $20.6 million, marking the highest net revenue quarter since the launch of Jeuveau.
- The company settled the International Trade Commission case and related litigation.
- Evolus eliminated $127 million of debt and payment obligations.
- The pro forma cash position was $57 million as of December 31, 2020.
Headline financials
Revenue & EPS history
Evolus · Revenue · Quarterly
$20.6M
Forward guidance
The Allergan/Medytox Settlement Agreements and the settlement agreement with Daewoong are expected to temporarily impact the company’s gross margin profile negatively through September 2022. The company anticipates 2021 full year gross margin will be between 50% and 55%.
Headwinds
- Gross margin profile is expected to be negatively impacted through September 2022 due to settlement agreements.
- 2021 full year gross margin is anticipated to be between 50% and 55%.
- Settlement with Daewoong is expected to impact gross margin profile negatively.
- Settlement Agreements will impact company's gross margin profile negatively.
- Gross margin percentage in the United States to return to the levels seen in fiscal year 2020 only following September 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+0.5%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+35.4%
Q4 2025
Best reaction
-26.9%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | +19.3% | — | |
| Q4 2025 | +35.4% | +29.5% | -2.4% | |
| Q3 2025 | +5.4% | +2.6% | +0.6% | |
| Q1 2025 | -14.2% | -13.9% | -14.6% | |
| Q4 2024 | -1.3% | -11.6% | -25.5% | |
| Q3 2024 | -13.3% | -20.4% | -23.2% | |
| Q2 2024 | +15.2% | +9.2% | +30.4% | |
| Q1 2024 | -1.0% | -4.8% | -7.4% | |
| Q4 2023 | -0.3% | -0.1% | -6.0% | |
| Q3 2023 | +9.7% | +0.4% | +20.3% | |
| Q2 2023 | -1.2% | -8.3% | -2.6% | |
| Q1 2023 | +17.8% | +14.9% | -3.9% | |
| Q4 2022 | -6.4% | -7.7% | -8.5% | |
| Q3 2022 | -8.4% | -3.2% | -1.6% | |
| Q2 2022 | -26.9% | -28.3% | -30.3% | |
| Q1 2022 | +9.2% | +29.0% | +20.4% | |
| Q4 2021 | +1.8% | +3.0% | +25.0% | |
| Q3 2021 | -9.5% | -10.0% | -33.3% | |
| Q2 2021 | -6.9% | +1.7% | -15.1% | |
| Q1 2021 | -0.9% | +2.4% | +41.1% | |
| Q4 2020 | -21.1% | -28.2% | -43.0% | |
| Q3 2020 | -1.9% | +2.3% | +23.9% | |
| Q2 2020 | +6.6% | +6.0% | +2.6% | |
| Q1 2020 | +4.8% | -9.7% | +32.9% | |
| Q4 2019 | -3.4% | -8.1% | -51.9% | |
| Q3 2019 | -2.2% | -10.7% | -20.3% | |
| Q2 2019 | -10.9% | -21.8% | -6.7% | |
| Q1 2019 | -7.5% | -5.1% | -46.4% | |
| Q4 2018 | +7.0% | -3.3% | -2.7% | |
| Q3 2018 | -5.8% | -6.6% | -10.6% | |
| Q2 2018 | +6.0% | +8.2% | +34.8% | |
| Q1 2018 | +27.9% | +38.9% | +142.4% | |
| Q4 2017 | +8.5% | +9.1% | -15.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro